FDA OKs accelerated approval to frontline Hyrnuo for non-small cell lung cancer

The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer.The approval of sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals), which expands upon the agent’s existing indication for patients who received systemic therapy, is dependent on the detection of HER2 tyrosine kinase